{"disease":{"id":"gastric-cancer","name":"Gastric Cancer","therapeutic_area":"Oncology","data":{"aiSummary":"The treatment landscape for gastric cancer is evolving, with a focus on personalized medicine. HER2-targeted therapies like trastuzumab have improved outcomes in HER2-positive patients. Immunotherapy with PD-1 inhibitors shows promise in MSI-H tumors. Ongoing research explores novel therapies, including ADCs and combinations, to address unmet needs and improve survival rates across all subtypes. The use of biomarkers to guide treatment decisions is becoming increasingly important.","drug_count":12,"description":"Gastric cancer is a malignancy that develops in the lining of the stomach. It often presents with vague symptoms, leading to late-stage diagnosis. Treatment involves a combination of surgery, chemotherapy, and targeted therapies, depending on the stage and molecular profile of the tumor.","subtype_count":11},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.927Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"nivolumab","indication_name":"Unresectable, advanced or recurrent gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opdivo","generic_name":"nivolumab","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Programmed cell death protein 1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":79,"revenue":"9200","mechanism":"Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells."},{"drug_id":"trastuzumab","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"trastuzumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 receptor, subdomain IV","drug_class":"Antibody-drug conjugate (ADC)","quality_score":82,"revenue":"2900","mechanism":"HER2-targeted antibody-drug conjugate delivering microtubule inhibitor DM1 to HER2-overexpressing cells."},{"drug_id":"tislelizumab","indication_name":"Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tevimbra","generic_name":"TISLELIZUMAB","company_name":"Beigene","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":50,"revenue":"900","mechanism":"Tevimbra blocks the PD-1 receptor, allowing the immune system to recognize and attack cancer cells."},{"drug_id":"adriacin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-dkst","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"OGIVRI","generic_name":"TRASTUZUMAB-DKST","company_name":"MYLAN GMBH","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"trazimera","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Herceptin","generic_name":"Trastuzumab-Qyyp","company_name":"Roche","drug_phase":"marketed","molecular_target":"HER2 (c-erbB2) proto-oncogene transmembrane receptor protein","drug_class":"HER2/neu receptor antagonist monoclonal antibody","quality_score":64,"revenue":null,"mechanism":"Trastuzumab inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity."},{"drug_id":"liposomal-doxorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"herceptin","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Herceptin","company_name":"National Cancer Institute (NCI)","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunomycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"trastuzumab-herceptin","indication_name":"Human epidermal growth factor 2 positive gastric cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trastuzumab (Herceptin)","generic_name":"trastuzumab-herceptin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"capecitabine","indication_name":"Treatment of unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."},{"drug_id":"trastuzumab-anns","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"KANJINTI","generic_name":"TRASTUZUMAB-ANNS","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"HER2/neu Receptor Antagonist [EPC]","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"mitomycin","indication_name":"Metastatic Gastric Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mitozytrex","generic_name":"MITOMYCIN","company_name":"Kyowa Kirin Co., Ltd.","drug_phase":"marketed","molecular_target":"Indoleamine 2,3-dioxygenase 1","drug_class":"Alkylating Drug [EPC]","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"trastuzumab-bs","indication_name":"Gastric Cancer","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"TRASTUZUMAB BS","generic_name":"trastuzumab-bs","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"","drug_class":"Regimen A or regimen B is used for HER2-overexpressing breast cancer.  RegimenB is used for HER2-ove","quality_score":null,"revenue":null,"mechanism":"Regimen A or regimen B is used for HER2-overexpressing breast cancer.  RegimenB is used for HER2-ove"}],"offLabel":[],"totalMarketed":17,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05291728","title":"Screening for Early Gastric Cancer in Shaanxi Province","phase":"","overall_status":"RECRUITING","enrollment_count":12500000,"lead_sponsor_name":"Second Affiliated Hospital of Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT06632886","title":"AI-Assisted Non-Contrast CT for Multi-Cancer Screening","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Guo ShiWei","has_results":false},{"nct_id":"NCT07067983","title":"Clinical Evaluation of GRAPE Model for Gastric Cancer Screening","phase":"","overall_status":"RECRUITING","enrollment_count":1000000,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05934058","title":"Genomic and Dietary Aspects in Gastric Cancer Risk","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":383980,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06078930","title":"Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT03900910","title":"Gastric Cancer Prevention for Indigenous Peoples","phase":"NA","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT03793335","title":"Individually Tailored Strategies for the Precision Prevention of Gastric Cancer and Colorectal Cancer in the Community","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40000,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT00342654","title":"Nutrition Intervention Trials in Linxian Follow-up Study","phase":"","overall_status":"COMPLETED","enrollment_count":32902,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06506825","title":"Construction and Application of Database of Hebei Provincial Gastric Cancer Collaborative Network Driven by Artificial Intelligence Technology","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT05540119","title":"Swedish Oesophago-Gastric Study","phase":"","overall_status":"UNKNOWN","enrollment_count":25000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06301464","title":"Pepsinogen II and Helicobacter Pylori Test in Gastric Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24000,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT05561504","title":"Helicobacter Pylori Local Prevalence and Antibiotic Resistance","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT03471494","title":"GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":15958,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT06943807","title":"Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT07032961","title":"A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT04958720","title":"Spanish Registry of Esophagogastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Fundación Sociedad Española de Oncologia Médica","has_results":false},{"nct_id":"NCT06943768","title":"Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":9654,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07213115","title":"Epidemiology and Treatment of Gastric Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":8582,"lead_sponsor_name":"Medizinische Hochschule Brandenburg Theodor Fontane","has_results":false},{"nct_id":"NCT07250347","title":"AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT","phase":"","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT00341276","title":"Esophageal Cancer Genetics Studies","phase":"","overall_status":"COMPLETED","enrollment_count":7705,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07525765","title":"AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"First Affiliated Hospital of Zhejiang University","has_results":false},{"nct_id":"NCT06275204","title":"H. Pylori Screen-and-treat Study in a Population of Young Adults","phase":"","overall_status":"RECRUITING","enrollment_count":6800,"lead_sponsor_name":"University of Latvia","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT05775120","title":"Epidemiology of Helicobacter Pylori Infection in Moscow","phase":"","overall_status":"UNKNOWN","enrollment_count":5121,"lead_sponsor_name":"Moscow Clinical Scientific Center","has_results":false},{"nct_id":"NCT07104214","title":"Development and Validation of a Risk Prediction Model for Gastric Retention in Patients Undergoing Sedated Gastroscopy","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT04957407","title":"The Research of Constructing a Risk Assessment Model for Gastric Cancer Based on Machine Learning","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07243847","title":"Recurrence and Prognosis Prediction Model for Gastric Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":5000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04989153","title":"Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT06384300","title":"Financial Incentives and Motivational Intervention to Improve Gastric Cancer Screening in China","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06943794","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":4824,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05368636","title":"Combining Tongue and Gastric Cancer Cascade With Artificial Intelligence","phase":"","overall_status":"UNKNOWN","enrollment_count":4000,"lead_sponsor_name":"Shandong University","has_results":false},{"nct_id":"NCT07486518","title":"A Multicentre Prospective Cohort Study of The Gastric Precancerous Epithelial Pathway Using High-Definition Endoscopy And Histopathology In India","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Asian Institute of Gastroenterology, India","has_results":false},{"nct_id":"NCT06606912","title":"Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Gastric Cancer Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":4000,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT06337279","title":"Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk","phase":"","overall_status":"COMPLETED","enrollment_count":3820,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03978481","title":"Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":3700,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT06337266","title":"A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":3622,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT05458388","title":"Different Endoscopic Gastric Cancer Risk Assessments","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3500,"lead_sponsor_name":"Yanqing Li","has_results":false},{"nct_id":"NCT06686966","title":"Prediction of Postoperative Complications and Survival in Gastric Cancer Using Preoperative Blood Markers","phase":"","overall_status":"COMPLETED","enrollment_count":3400,"lead_sponsor_name":"First Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT06185907","title":"In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk Factors","phase":"","overall_status":"COMPLETED","enrollment_count":3238,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06370143","title":"A Study Collecting Health Information to Understand and Prevent Gastric Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3200,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07072429","title":"Annual Hospital Volume and and Short-term Postoperative Outcomes After Gastric Cancer Resection","phase":"","overall_status":"COMPLETED","enrollment_count":3112,"lead_sponsor_name":"Cantonal Hospital of St. Gallen","has_results":false},{"nct_id":"NCT07312500","title":"Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06896370","title":"An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03228095","title":"Volatiles in Breath and Headspace Analysis - Diagnostic Markers","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"University of Latvia","has_results":false},{"nct_id":"NCT06713421","title":"Effect of Premedication With Pronase on Mucosal Cleanliness During EGD","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06489288","title":"ERAS in Totally Laparoscopic Total Gastrectomy for Gastric Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2656,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05693519","title":"GastroIntestinal Cancer in Children and Adolescents","phase":"","overall_status":"UNKNOWN","enrollment_count":2500,"lead_sponsor_name":"Paul G. Kemps, MD","has_results":false},{"nct_id":"NCT04214119","title":"EsophaCap for the Detection of Early Esophageal Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"Johns Hopkins University","has_results":false},{"nct_id":"NCT04720521","title":"Application of OE in Diagnosis of EGC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2454,"lead_sponsor_name":"Changhai Hospital","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}